Taysha Gene Therapies
TSHA
48 hedge funds and large institutions have $388M invested in Taysha Gene Therapies in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 26 increasing their positions, 5 reducing their positions, and 8 closing their positions.
420% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 5
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
8% more capital invested
Capital invested by funds: $358M → $388M (+$29.7M)
4% more funds holding
Funds holding: 46 → 48 (+2)
1.54% more ownership
Funds ownership: 46.77% → 48.31% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.3M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$9.11M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$6.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.53M |
| 5 |
JP Morgan Chase
New York
|
+$4.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
-$18.2M |
| 2 |
CC
Casdin Capital
New York
|
-$16.7M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.46M |
| 4 |
VA
VR Adviser
New York
|
-$2.45M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.35M |
TSHA Hedge Fund Activity: Q2 2021 in Review
48 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2021, worth a combined $388M — up 8.3% from $358M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new TSHA positions and 8 closed out — a net gain of 2 holders — while 26 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $16.3M. The largest seller was University of Texas/Texas AM Investment Management Co (UTIMCO), cutting an estimated $18.2M.
- 48 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2021, up from 46 in Q1 2021.
- Funds reported $388M of Taysha Gene Therapies stock for Q2 2021, up 8.3% quarter-over-quarter.
- 10 funds opened new Taysha Gene Therapies positions in Q2 2021 and 8 closed out, a net change of +2 holders.
- The largest Taysha Gene Therapies buyer in Q2 2021 was BlackRock, an estimated $16.3M added.
- The largest Taysha Gene Therapies seller in Q2 2021 was University of Texas/Texas AM Investment Management Co (UTIMCO), an estimated $18.2M sold.
Based on aggregated 13F filings for Q2 2021.